Cas: 6285-57-0 was involved in experiment | Fibers and Polymers 2020

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Product Details of 6285-57-0) inhibits the activity of amines, which are small molecules found in many pharmaceuticals. The chemical structure of this drug contains one or more methylene groups that can be activated by diazonium salt to form an intermediate molecule with a reactive amine group.

Song, Xiyu;Hou, Aiqin;Xie, Kongliang;Hu, Tingli published 《Synthesis and Dyeing Properties of New Bi-heterocyclic Disperse Dyes Containing Pyridone Group for Polyester Fabrics》 in 2020. The article was appeared in 《Fibers and Polymers》. They have made some progress in their research.Product Details of 6285-57-0 The article mentions the following:

A series of novel bi-heterocyclic disperse dyes containing N-ethyl-3-cyano-4-methyl-6-hydroxy-2-pyridine group were synthesized. The structures of the bi-heterocyclic dyes were characterized by Fourier transform IR spectroscopy (FT-IR), NMR spectroscopy (1H-NMR), UV-vis spectrophotometry, and elemental anal. The distinct spectral behavior and solvatochromic effect of the dyes were discussed. The dyeing properties of the dyes for polyethylene terephthalate (PET) fabric were investigated. Novel bi-heterocyclic disperse dyes had higher molar absorption coefficient, good color strength, and excellent fastness properties, especially light fastness. The bi-heterocyclic disperse dyes have potential research value in the development of high light resistant dyes and functional dyes. The experimental procedure involved many compounds, such as 6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) .

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Product Details of 6285-57-0) inhibits the activity of amines, which are small molecules found in many pharmaceuticals. The chemical structure of this drug contains one or more methylene groups that can be activated by diazonium salt to form an intermediate molecule with a reactive amine group.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Lubinsky, Anthony Steven et al. published new progress in experiments with the help of cas: 55981-09-4

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), a thiazolide compound, is a antiparasitic drug with structure similar to niclosamide.Quality Control of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate

Quality Control of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetateIn 2022, Lubinsky, Anthony Steven;Brosnahan, Shari B.;Lehr, Andrew;Elnadoury, Ola;Hagedorn, Jacklyn;Garimella, Bhaskara;Bender, Michael T.;Amoroso, Nancy;Artigas, Antonio;Bos, Lieuwe D. J.;Kaufman, David published 《Inhaled pulmonary vasodilators are not associated with improved gas exchange in mechanically ventilated patients with COVID-19: A retrospective cohort study》. 《Journal of Critical Care》published the findings. The article contains the following contents:

Measure the effect of inhaled pulmonary vasodilators on gas exchange in mech. ventilated patients with COVID-19. A retrospective observational cohort study at three New York University Hospitals was performed including eighty-four mech. ventilated SARS Cov-2 nasopharyngeal PCR pos. patients, sixty nine treated with inhaled nitric oxide (iNO) and fifteen with inhaled epoprostenol (iEPO). The primary outcomes were change in PAO2:FIO2 ratio, oxygenation Index (OI), and ventilatory ratio (VR) after initiation of inhaled pulmonary vasodilators. There was no significant change in PAO2:FIO2ratio after initiation of iNO (mean – 4.1, 95% CI -17.3-9.0, P = 0.54) or iEPO (mean – 3.4, 95% CI -19.7-12.9, P = 0.66), in OI after initiation of iNO (mean 2.1, 95% CI-0.04-4.2, P = 0.054) or iEPO (mean – 3.4, 95% CI -19.7-12.9, P = 0.75), or in VR after initiation of iNO (mean 0.17, 95% CI -0.03-0.36, P = 0.25) or iEPO (mean 0.33, 95% CI -0.0847-0.74, P = 0.11). PAO2:FIO2, OI and VR did not significantly change over a five day period starting the day prior to drug initiation in patients who received either iNO or iEPO assessed with a fixed effects model. Inhaled pulmonary vasodilators were not associated with significant improvement in gas exchange in mech. ventilated patients with COVID-19. And 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) was used in the research process.

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), a thiazolide compound, is a antiparasitic drug with structure similar to niclosamide.Quality Control of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Cas: 6285-57-0 was involved in experiment | Bioorganic & Medicinal Chemistry Letters 2020

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0) has been used:
as model analyte for voltammetric determination of electrochemically reducible organic substances;
in the synthesis of 2-methyl-4-nitro-2H-pyrazole-3-carboxylic acid[2-(cyclohexanecarbonylamino)benzothiazol-6-yl]amide derivatives;
in the preparation of push-pull nonlinear optical chromophores containing thiazole and benzothiazole acceptors;
as a base in dye production by diazotation reaction.

Zhang, Qing;Zhao, Kuantao;Zhang, Lixun;Jiao, Xiaoyu;Zhang, Yongjie;Tang, Chunlei published 《Synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors》 in 2020. The article was appeared in 《Bioorganic & Medicinal Chemistry Letters》. They have made some progress in their research.Reference of 6-Nitrobenzo[d]thiazol-2-amine The article mentions the following:

As a class III receptor tyrosine kinase (RTK), FMS-like tyrosine kinase 3 (FLT3) is always overexpressed in many cases of acute leukemia. This paper studies the structure-based synthesis and biol. evaluation of diaryl urea derivatives as FLT3 inhibitors. Encouragingly, compounds 1-(3-(tert-butyl)isoxazol-5-yl)-3-(4-(7-methoxybenzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea , 1-(3-(tert-butyl)isoxazol-5-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea , 1-(5-(tert-butyl)isoxazol-3-yl)-3-(2-(4-(2-morpholinoethoxy)phenyl)benzo[d]imidazo[2,1-b]thiazol-7-yl)urea , and 1-(3-(tert-butyl)isoxazol-5-yl)-3-(2-(4-(2-morpholinoethoxy)phenyl)benzo[d]imidazo[2,1-b]thiazol-7-yl)urea showed excellent biol. activities in a low nanomolar range. In particular, compound 1-(3-(tert-butyl)isoxazol-5-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea demonstrated significant inhibitory potency against FLT3-ITD (IC50 = 5.60 nM) and better antiproliferative activity than quizartinib against MV4-11 cell line (IC50 = 0.176 nM). Compound 1-(3-(tert-butyl)isoxazol-5-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea for the treatment of acute myeloid leukemia could be very promising. The experimental procedure involved many compounds, such as 6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) .

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0) has been used:
as model analyte for voltammetric determination of electrochemically reducible organic substances;
in the synthesis of 2-methyl-4-nitro-2H-pyrazole-3-carboxylic acid[2-(cyclohexanecarbonylamino)benzothiazol-6-yl]amide derivatives;
in the preparation of push-pull nonlinear optical chromophores containing thiazole and benzothiazole acceptors;
as a base in dye production by diazotation reaction.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Explore more uses of cas: 6285-57-0 | Journal of Applicable Chemistry (Lumami, India)

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Category: thiazole) is an antimicrobial agent that inhibits bacterial growth by cleaving the peptide bonds of proteins. It has been shown to be active against a number of microorganisms, including Gram-positive and Gram-negative bacteria, as well as fungi.

Pawde, A. V.;Kadam, D. B.;Vartale, S. P. published 《Synthesis and evaluation of antimicrobial, antioxidant activities of pyrido[3,2-d]pyrazolo[3,2-b]-4H-pyrimido[5,6-e]-4H-pyrimido[2,3-b]benzothiazole derivatives》. The research results were published in《Journal of Applicable Chemistry (Lumami, India)》 in 2019.Category: thiazole The article conveys some information:

The objective of the present investigation was to synthesize 3-cyano-4-oxo-2-(methylthio)-6-N-Ph pyrido[3,2-d]pyrazolo[3,2-b]pyrimidine by condensation of 1-phenyl-1H-pyrazolo[3,4-b]pyridine-3-amine with Et cyano bis(methylthio)acrylate which on further condensation with various 2-amino 1/2/3/4-substituted benzothiazoles gives 15-imino-14-oxo-12-N-Ph pyrido[3,2-d]pyrazolo[3,2-b]-4H-pyrimido[5,6-e]-4H-pyrimido[2,3-b]benzothiazole and their 1/3 substituted derivatives I (R1 = H, CH3, OCH3, Cl, NO2; R2 = H, CH3). These newly synthesized compounds were further screened for antimicrobial and antioxidant properties. The experimental procedure involved many compounds, such as 6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) .

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Category: thiazole) is an antimicrobial agent that inhibits bacterial growth by cleaving the peptide bonds of proteins. It has been shown to be active against a number of microorganisms, including Gram-positive and Gram-negative bacteria, as well as fungi.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Cas: 6285-57-0 | Jakopec, Silviopublished an article in 2022

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Synthetic Route of C7H5N3O2S) inhibits the activity of amines, which are small molecules found in many pharmaceuticals. The chemical structure of this drug contains one or more methylene groups that can be activated by diazonium salt to form an intermediate molecule with a reactive amine group.

Jakopec, Silvio;Pantalon Juraj, Natalija;Brozovic, Anamaria;Jadresko, Dijana;Peric, Berislav;Kirin, Srecko I.;Raic-Malic, Silvana published 《Ferrocene conjugates linked by 1,2,3-triazole and their Zn(II) and Cu(II) complexes: Synthesis, characterization and biological activity》. The research results were published in《Applied Organometallic Chemistry》 in 2022.Synthetic Route of C7H5N3O2S The article conveys some information:

Ferrocene derivatives with mono- Py2NCH2Trz-1-R (8ac; Py = 2-pyridyl, Trz = 1,2,3-triazol-5-yl; R = Fc, FcCH2, FcCHMe) and bis-1,2,3-triazolyl fc(CH2-1-TrzCH2NPy2)2(9, fc = 1,1′-ferrocenediyl) and ArN(CH2Trz-1-R)2 (10a13c; R = Fc, FcCH2, FcCHMe; Ar = Ph, 2-benzothiazolyl, 6-chloro-2-benzothiazolyl, 6-nitro-2-benzothiazolyl) chelating groups were synthesized by regioselective copper(I)-catalyzed 1,3-dipolar cycloaddition of terminal alkynes with ferrocene azides. Metal complexes of the ligands were prepared with Cu(II) and Zn(II) salts. Crystal structures of ligands 9 and 11a were determined, as well as the structures of complexes [Cu(8a)2](CF3SO3)2 (8a-Cu) and [Cu(8c)2(MeOH)2](BF4)2 (8c-Cu). In addition to NMR and UV-Vis spectroscopy, the metal complexes were characterized by cyclic voltammetry. The cytotoxic effect of ferrocene conjugates and their Zn(II) and Cu(II) complexes was explored, and cell cycle anal. was performed. The complex [Cu(8c)2](CF3SO3)2 showed the most prominent and selective cytotoxicity on cervical carcinoma (HeLa), ovarian cancer (MES-OV), non-small cell lung cancer (A549) and breast carcinoma (MDA-MB-231) cells. This complex increased cell population in the S and G2/M phase of the cell cycle, which was accompanied by an increase of the cells present in the sub-G0/G1 fraction. And 6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) was used in the research process.

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Synthetic Route of C7H5N3O2S) inhibits the activity of amines, which are small molecules found in many pharmaceuticals. The chemical structure of this drug contains one or more methylene groups that can be activated by diazonium salt to form an intermediate molecule with a reactive amine group.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Explore more uses of cas: 55981-09-4 | International Journal for Parasitology

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been used: to test its anti-viral activity against chikungunya virus as an antiprotozoal agent to test its effect on cell viability in various cancer cell lines; to test its effect on human cytomegalovirus (HCMV) infected human fibroblast HFF cellsRecommanded Product: 55981-09-4

Lu, Chunxia;Liu, Xianyong;Liu, Jie;Tang, Xinming;Zhu, Guan;Striepen, Boris;Suo, Xun published 《Immunocompetent rabbits infected with Cryptosporidium cuniculus as an animal model for anti-cryptosporidial drug testing》 in 2022. The article was appeared in 《International Journal for Parasitology》. They have made some progress in their research.Recommanded Product: 55981-09-4 The article mentions the following:

Cryptosporidium is one of the leading causes of diarrheal disease in humans and animals, which can be severe and deadly in neonates and immunocompromised hosts. Studies on the biol. of Cryptosporidium and drug discovery efforts have been hindered by a number of factors including the limited availability of animal models. Here, we report the establishment and characterization of an immunocompetent rabbit model for infection with Cryptosporidium cuniculus. By testing four known anti-cryptosporidial compounds (nitazoxanide, baicalein, curcumin and matrine), we showed that the rabbit could be used as an alternative animal model for evaluating anti-cryptosporidial drug efficacy in vivo.2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) were involved in the experimental procedure.

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been used: to test its anti-viral activity against chikungunya virus as an antiprotozoal agent to test its effect on cell viability in various cancer cell lines; to test its effect on human cytomegalovirus (HCMV) infected human fibroblast HFF cellsRecommanded Product: 55981-09-4

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Cas: 55981-09-4 | Parpia, Tarina et al. made new progress in 2022

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), a thiazolide compound, is a antiparasitic drug with structure similar to niclosamide.SDS of cas: 55981-09-4

Parpia, Tarina;Svensen, Erling;Elwood, Sarah;Wanjuhi, Anne;Blacy, Ladislaus;Bayo, Eliwaza;Houpt, Eric;McQuade, Elizabeth Rogawski;DeBoer, Mark;Platts-Mills, James;Mduma, Estomih;Scharf, Rebecca published 《Cognitive outcomes at 18 months: findings from the early life interventions for childhood growth and development in Tanzania (ELICIT) trial》 in 2022. The article was appeared in 《American Journal of Tropical Medicine and Hygiene》. They have made some progress in their research.SDS of cas: 55981-09-4 The article mentions the following:

Micronutrient deficiencies and enteric infections neg. impact child growth and development. We enrolled children shortly after birth in a randomized, placebo-controlled, 2 x 2 factorial interventional trial in Haydom, Tanzania, to assess nicotinamide and/or antimicrobials (azithromycin and nitazoxanide) effect on length at 18 mo of age. Cognitive score at 18 mo using the Malawi Developmental Assessment Tool (MDAT), which includes gross motor, fine motor, language, and social assessments, was a secondary outcome. Here, we present the MDAT results of 1,032 children. There was no effect of nicotinamide (change in development-for-age Z score [DAZ] -0.08; 95% CI: -0.16, 0) or antimicrobials (change in DAZ 0.04; 95% CI: -0.06, 0.13) on overall MDAT score. The interventions had no effect on cognitive outcomes in subgroups defined by gender, socioeconomic status, birthweight, and birth season or on MDAT subscores. Further analyses are needed to identify targetable risk factors for impaired cognitive development in these settings. The experimental procedure involved many compounds, such as 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) .

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), a thiazolide compound, is a antiparasitic drug with structure similar to niclosamide.SDS of cas: 55981-09-4

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Shawky, D et al. published new experimental results with the assistance of cas: 55981-09-4

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been approved as an orphan drug for the treatment of diarrhea in children (age, 1–11 years) and is associated with giardiasis, but it also is approved for diarrhea caused by crytosporidiosis in patients with AIDS.Safety of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate

Safety of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetateIn 2022, Shawky, D;Salamah, A M;Abd-Elsalam, S M;Habba, E;Elnaggar, M H;Elsawy, A A;Baiomy, N;Bahaa, M M;Gamal, R M published 《Nitazoxanide-based therapeutic regimen as a novel treatment for Helicobacter pylori infection in children and adolescents: a randomized trial.》. 《European review for medical and pharmacological sciences》published the findings. The article contains the following contents:

OBJECTIVE: Antibiotic resistance and poor patient compliance with treatment cause Helicobacter pylori to show increased resistance to typical first-line therapeutic regimens. This study aimed to evaluate the efficacy of the new nitazoxanide-based treatment regimens for Helicobacter pylori infection vs. the current metronidazole-based regimens to address the problem of increasing metronidazole resistance. PATIENTS AND METHODS: This randomized clinical trial enrolled 100 patients with Helicobacter pylori infection. The patients were randomly assigned to one of two groups: group I received nitazoxanide-based triple therapy (nitazoxanide, proton pump inhibitor, and clarithromycin) for 14 days, whereas group II received standard treatment (metronidazole, omeprazole, and clarithromycin) for 14 days. On enrollment and after six weeks of treatment, all patients underwent careful history taking, full clinical examination, laboratory investigations (complete blood count, liver and renal function tests), and Helicobacter pylori stool antigen testing. RESULTS: Of the patients, 92% in the nitazoxanide group and 84% in the metronidazole group recovered from infection, with no statistically significant difference between the two groups. Patients in the nitazoxanide group showed a 54% lower risk of resistant infection (odds ratio, 0.5; 95% confidence interval, 0.161-1.555) than those in the metronidazole group. CONCLUSIONS: The nitazoxanide-based therapeutic regimen produced higher eradication rates than the standard treatment. However, the difference was not substantial in this particular group of patients.2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) were involved in the experimental procedure.

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been approved as an orphan drug for the treatment of diarrhea in children (age, 1–11 years) and is associated with giardiasis, but it also is approved for diarrhea caused by crytosporidiosis in patients with AIDS.Safety of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Learn more about cas: 55981-09-4 | Acta Parasitologica 2021

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been used: to test its anti-viral activity against chikungunya virus as an antiprotozoal agent to test its effect on cell viability in various cancer cell lines; to test its effect on human cytomegalovirus (HCMV) infected human fibroblast HFF cellsRecommanded Product: 55981-09-4

Lima, Nayana F.;Picanco, Guaraciara A.;Costa, Tatiane L.;Lino, Ruy de Souza Jr.;Vinaud, Marina C. published 《In Vivo Treatment with the Combination of Nitazoxanide and Flubendazole Induces Gluconeogenesis and Protein Catabolism in Taenia crassiceps cysticerci》. The research results were published in《Acta Parasitologica》 in 2021.Recommanded Product: 55981-09-4 The article conveys some information:

Abstract: Purpose: Cysticercosis is the presence of Taenia solium larva in humans or swines tissues. It is a public health problem related to bad hygienic habits and consumption of infected pork. T. crassiceps is a widely used cysticercosis exptl. model. The combination of two effective drugs such as nitazoxanide (NTZ) and flubendazole (FBZ) may potentialize their effect. The aim of this study was to use biochem. anal. to determine the metabolic impact of the combination of NTZ and FBZ on cysticerci inoculated i.p. in mice. Methods: Balb/c mice i.p. infected with T. crassiceps cysticerci received a single oral dose NTZ/FBZ (50 mg/kg). 24 h after the treatment the cysticerci were removed, frozen and analyzed by high performance liquid chromatog. regarding the detection of the following metabolic pathways: glycolysis, gluconeogenesis, homolactic fermentation, tricarboxylic acid cycle, proteins catabolism and fatty acids oxidation Results: The treatment with the drugs combination induced a statistically significant increase in gluconeogenesis and in protein catabolism when compared to the control groups. Conclusion: The drugs combination is potentialized and capable of causing greater metabolic stress than the sep. treatment with NTZ or FBZ, showing its potential for an alternative cysticercosis treatment.2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) were involved in the experimental procedure.

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been used: to test its anti-viral activity against chikungunya virus as an antiprotozoal agent to test its effect on cell viability in various cancer cell lines; to test its effect on human cytomegalovirus (HCMV) infected human fibroblast HFF cellsRecommanded Product: 55981-09-4

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Learn more about cas: 55981-09-4 | Journal of Cellular and Molecular Medicine 2022

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been used: to test its anti-viral activity against chikungunya virus as an antiprotozoal agent to test its effect on cell viability in various cancer cell lines; to test its effect on human cytomegalovirus (HCMV) infected human fibroblast HFF cellsSDS of cas: 55981-09-4

Xu, Junlin;Meng, Yajie;Peng, Lihong;Cai, Lijun;Tang, Xianfang;Liang, Yuebin;Tian, Geng;Yang, Jialiang published 《Computational drug repositioning using similarity constrained weight regularization matrix factorization: A case of COVID -19》. The research results were published in《Journal of Cellular and Molecular Medicine》 in 2022.SDS of cas: 55981-09-4 The article conveys some information:

Amid the COVID-19 crisis, we put sizeable efforts to collect a high number of exptl. validated drug-virus association entries from literature by text mining and built a human drug-virus association database. To the best of our knowledge, it is the largest publicly available drug-virus database so far. Next, we develop a novel weight regularization matrix factorization approach, termed WRMF, for in silico drug repurposing by integrating three networks: the known drug-virus association network, the drug-drug chem. structure similarity network, and the virus-virus genomic sequencing similarity network. Specifically, WRMF adds a weight to each training sample for reducing the influence of neg. samples (i.e. the drug-virus association is unassocd.). A comparison on the curated drug-virus database shows that WRMF performs better than a few state-of-the-art methods. In addition, we selected the other two different public datasets (i.e. Cdataset and HMDD V2.0) to assess WRMFs performance. The case study also demonstrated the accuracy and reliability of WRMF to infer potential drugs for the novel virus. In summary, we offer a useful tool including a novel drug-virus association database and a powerful method WRMF to repurpose potential drugs for new viruses. The experimental procedure involved many compounds, such as 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) .

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been used: to test its anti-viral activity against chikungunya virus as an antiprotozoal agent to test its effect on cell viability in various cancer cell lines; to test its effect on human cytomegalovirus (HCMV) infected human fibroblast HFF cellsSDS of cas: 55981-09-4

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica